3-ethyl-6-fluoro-4-hydroxy-2(1H)-quinolinone | 345913-59-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-ethyl-6-fluoro-4-hydroxy-2(1H)-quinolinone
• 英文别名: 3-ethyl-6-fluoro-4-hydroxyquinolin-2(1H)-one；3-ethyl-6-fluoro-4-hydroxy-1H-quinolin-2-one
• CAS: 345913-59-9
• 化学式: C₁₁H₁₀FNO₂
• 分子量: 207.204
• InChiKey: IGOFJFGYZRONGV-UHFFFAOYSA-N

物化性质

• 沸点：
  401.5±45.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-ethyl-6-fluoro-4-hydroxy-2(1H)-quinolinone 在 sodium hydride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-{[tert-Butyl(dimethyl)silyl]oxy}-3-ethyl-6-fluoro-4-(2,2,2-trifluoroethoxy) quinoline
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r
• 作为产物：
  描述：

  ethyl 2-[(4-fluoroanilino)carbonyl]butanoate 在 盐酸 作用下， 以 sodium hydroxide 为溶剂， 以43%的产率得到3-ethyl-6-fluoro-4-hydroxy-2(1H)-quinolinone
  参考文献：
  名称：

  Quinolone compounds for use in treating viral infections

  摘要：

  本发明涉及喹诺酮化合物及其在治疗病毒感染中的应用。

  公开号：

  US20030069271A1

文献信息

• Design, synthesis and antitubercular potency of 4-hydroxyquinolin-2(1H)-ones
  作者：Maíra Bidart de Macedo、Roman Kimmel、Damijana Urankar、Martin Gazvoda、Antonio Peixoto、Freya Cools、Eveline Torfs、Luc Verschaeve、Emerson Silva Lima、Antonín Lyčka、David Milićević、Antonín Klásek、Paul Cos、Stanislav Kafka、Janez Košmrlj、Davie Cappoen

  DOI：10.1016/j.ejmech.2017.06.061

  日期：2017.9

  None of these selected derivatives showed significant acute toxicity against MRC-5 cells or early signs of genotoxicity in the Vitotox™ assay at the active concentration range. The structure activity study relation provided some insight in the further favourable substitution pattern at the 4-hydroxyquinolin-2(1H)-one scaffold and finally 6-fluoro-4-hydroxy-3-phenylquinolin-2(1H)-one (38) was selected as

  在这项研究中，设计了一个由50个成员组成的，由4-羟基喹啉2（1 H）-取代基和两个密切相关的类似物组成的文库，对该文进行了计算机模拟评分，随后进行了合成。共有13个共有3-苯基取代基的13种衍生物对10μM以下的结核分枝杆菌H37Ra和牛分枝杆菌的抑制作用最小低于15μM的AN5A对快速生长的分枝杆菌物种无活性。在活性浓度范围内，在Vitotox™分析中，这些选择的衍生物均未显示出对MRC-5细胞具有明显的急性毒性或遗传毒性的早期迹象。结构活性研究的关系为4-羟基喹啉-2（1 H）-one支架和6-氟-4-羟基-3-苯基喹啉-2（1 H）-one（1 ）的进一步有利的取代方式提供了一些见识。38）被选为库中最有前途的成员，MIC为3.2μM，针对MRC-5的CC 50为67.4μM。
• QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1244629A2

  公开（公告）日：2002-10-02
• [EN] QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS<br/>[FR] COMPOSES DE QUINOLONE UTILISES DANS LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：GLAXO GROUP LTD

  公开号：WO2001046150A2

  公开（公告）日：2001-06-28

  The present invention relates to quinolone compounds, such as compounds of formula (Ia) wherein: R1 is hydrogen; R2 is oxygen or sulfur; R3 is trifluoromethyl; cyano; C¿1-8?alkyl optionally substituted with C1-8alkyl or trifluoromethyl; or OR?15¿, wherein R15 is C¿1-8?alkyl optionally substituted with C1-8alkyl; R?4 is OR11¿, wherein R11 is C¿2-8?alkenyl optionally substituted with C1-8alkyl; C1-8alkyl optionally substituted with C1-8alkyl; C6-14arylalkyl; C3-6cycloalkyl; C3-6cycloalkylalkyl; heterocyclealkyl; heterocyclealkynyl; C3-6cycloalkylalkenyl; C6-14arylalkynyl; C3-6cycloalkylalkynyl; SR?12¿, wherein R12 is C¿3-6?cycloalkyl; S(O)R?12¿, wherein R12 is C¿3-6?cycloalkyl; or NR?13R14¿ wherein R?13 and R14¿, which may be the same or different, are hydrogen or C¿1-8?alkyl, optionally substituted with C1-8alkyl; R?5¿ is hydrogen; nitro; halogen; C¿1-8?alkyl, optionally substituted with C1-8alkyl or trifluoromethyl; R?6¿ is hydrogen; halogen; C¿1-8?alkyl; cyano: trifluoromethyl; or OR?10¿ wherein R10 is C¿1-8?alkyl or trifluoromethyl; R?7¿ is hydrogen; C¿1-8?alkyl; halogen; C6-14aryl; C1-8alkylaryl; C2-8alkynyl; heteroaryl; or OR?9¿ wherein R9 is C¿1-8?alkyl; R?8¿ is hydrogen; halogen; cyano; nitro; or OR16, wherein R16 is hydrogen or C¿1-8?alkyl optionally substituted with C1-8alkyl or trifluoromethyl; and their use in the treatment of viral infections.